An alternative view is that the market has marked them down for...

An alternative view is that the market has marked them down for their execution against a very transient plan. No marketing self promoting can overcome this fact.

We need a CEO that will drive some stronger accountability against a fixed plan and properly communicate the gaps. I expect the incoming CEO will need to reset the latest version of the plan once again based on actual experience with global clinical trials. As such the timeframes are more likely to move further out than in. The lack of current momentum perhaps suggest this is now the consensus. But on a positive note the limited short term expectations can often surprise with change in sentiment.